Across TCGA pan-cancer cohorts, THEM6 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated THEM6 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher THEM6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated THEM6 expression acts as an unfavorable survival marker.
UCEC are the cancer types where THEM6 Mutation most reproducibly stratifies survival.